fda

FDA to take steps to ease shortages of drugs for COVID-19 patients on ventilators

pharmafile | April 21, 2020 | News story | Manufacturing and Production COVID-19, Ventilators, coronavirus 

The FDA is to allow small compound pharmacies to fill the shortages of medicines needed for patients with COVID-19 who are on ventilators.

The decision was taken as hospitals are struggling to acquire individual  prescriptions and purchase medicines from their traditional suppliers. These include painkillers, muscle relaxants, sedatives and anesthetics.

These shortages have increased drastically since the pandemic reached America. From January to March, the shortages of these drugs rose 87%, and between January and April it increased by 213% according to Vizient.

In its new guidance, the FDA said: “In light of unprecedented disruptions to, and demands on, the global pharmaceutical supply chain as a result of the Covid-19 pandemic, and in order to respond to evolving regional conditions, additional flexibility is temporarily needed to ensure that treatment options are available when hospitals are unable to obtain FDA-approved drugs used for hospitalized patients with Covid-19.”

These types of compound pharmacies became controversial when in 2012 an outbreak of fungal meningitis killed dozens of people. It is felt that 60 of these deaths were due to a quality control breakdown at the now-defunct New England Compounding Center.

 In the aftermath, Congress created two classes of compounders in The Drug Quality and Security Act. One is the 503B compounder which ships large quantities out of state overseen by the FDA, and the 503B compounder which is overseen by state boards of pharmacy.

Conor Kavanagh

Related Content

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …

diana-polekhina-zbsthwt9vlc-unsplash_2

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …

Vaccine image

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive …

Latest content